SecSonar.com

Crinetics Pharmaceuticals, Inc. (CRNX)

Crinetics Pharmaceuticals, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Crinetics Pharmaceuticals, Inc. (CRNX) is a Biotechnology company based in US with a market capitalization of $3.7B. Revenue grew 640.7% year-over-year and free cash flow was negative at -$383.7M. This page tracks CRNX's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 437 employees · IPO Jul 18, 2018

Valuation

Valuation & price

$36.77 · as of May 17, 2026 · -34.8% vs 52w high

—

P/E ratio

Latest-FY diluted EPS

3.78

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$55.99$41.69$27.38Jul 25Dec 25Jul 26Jul 7, 25$29.06Jul 9, 25$32.33Jul 11, 25$31.93Jul 15, 25$31.83Jul 17, 25$33.02Jul 21, 25$30.95Jul 23, 25$30.98Jul 25, 25$30.99Jul 29, 25$29.27Jul 31, 25$28.59Aug 4, 25$28.22Aug 6, 25$28.53Aug 11, 25$27.38Aug 13, 25$30.09Aug 15, 25$30.72Aug 19, 25$29.43Aug 21, 25$29.40Aug 25, 25$30.09Aug 27, 25$30.40Aug 29, 25$30.99Sep 3, 25$34.65Sep 5, 25$35.61Sep 9, 25$36.50Sep 11, 25$33.73Sep 16, 25$34.10Sep 18, 25$35.48Sep 22, 25$33.72Sep 24, 25$35.18Sep 26, 25$45.91Sep 30, 25$41.65Oct 2, 25$41.51Oct 6, 25$41.68Oct 8, 25$44.43Oct 10, 25$44.93Oct 14, 25$44.05Oct 16, 25$42.31Oct 21, 25$42.85Oct 23, 25$40.08Oct 27, 25$44.34Oct 29, 25$42.90Oct 31, 25$43.50Nov 4, 25$42.51Nov 6, 25$43.49Nov 10, 25$41.45Nov 12, 25$42.82Nov 14, 25$42.67Nov 18, 25$43.01Nov 20, 25$41.97Nov 25, 25$44.71Nov 28, 25$45.56Dec 2, 25$45.01Dec 4, 25$47.42Dec 8, 25$47.40Dec 10, 25$48.06Dec 12, 25$50.49Dec 16, 25$48.61Dec 18, 25$45.14Dec 22, 25$49.24Dec 24, 25$48.71Dec 29, 25$47.52Jan 2, 26$46.73Jan 6, 26$45.95Jan 8, 26$53.24Jan 12, 26$55.35Jan 14, 26$55.42Jan 16, 26$55.99Jan 21, 26$55.41Jan 23, 26$53.18Jan 27, 26$52.97Jan 29, 26$51.88Feb 2, 26$49.35Feb 4, 26$47.43Feb 9, 26$46.01Feb 11, 26$47.61Feb 13, 26$42.70Feb 18, 26$43.45Feb 20, 26$43.44Feb 24, 26$44.52Feb 26, 26$43.74Mar 2, 26$40.68Mar 4, 26$39.51Mar 6, 26$38.23Mar 10, 26$37.35Mar 12, 26$36.51Mar 17, 26$37.89Mar 19, 26$35.82Mar 23, 26$34.71Mar 25, 26$36.34Mar 27, 26$33.67Mar 31, 26$36.32Apr 2, 26$37.23Apr 7, 26$38.41Apr 9, 26$39.63Apr 13, 26$38.66Apr 15, 26$39.77Apr 17, 26$41.00Apr 22, 26$39.10Apr 24, 26$38.33Apr 28, 26$38.15Apr 30, 26$38.78May 4, 26$41.25May 6, 26$41.71May 8, 26$37.48May 12, 26$36.91May 14, 26$38.31May 18, 26$34.70May 20, 26$36.27May 22, 26$36.80May 28, 26$36.01Jun 1, 26$34.52Jun 3, 26$33.09Jun 5, 26$32.92Jun 9, 26$34.97Jun 11, 26$33.53Jun 15, 26$35.12Jun 17, 26$35.75Jun 22, 26$35.38Jun 24, 26$36.18Jun 26, 26$36.70Jul 2, 26$42.23
$26.8552-week range$56.43
Loading valuation history…

Fundamentals

Key fundamentals

$3.7B

Market cap

640.7%

Revenue growth (YoY)

86.0%

Gross margin

-$383.7M

Free cash flow (USD)

-$979.3M

Net debt

Net cash position

16.4%

Share dilution

1/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2016 → 2025

FY 2016$589.0KFY 2017$2.0MFY 2018$2.4MFY 2019$1.2MFY 2020$71.0KFY 2021$1.1MFY 2022$4.7MFY 2023$4.0MFY 2024$1.0MFY 2025$7.7M
$589K$7.7M

Free cash flow by year

2016 → 2025

FY 2016$-5.7MFY 2017$-9.8MFY 2018$-20.5MFY 2019$-46.9MFY 2020$-62.2MFY 2021$-89.0MFY 2022$-116.9MFY 2023$-171.0MFY 2024$-229.8MFY 2025$-383.7M
-$5.7M-$383.7M

Gross margin by year

2021 → 2025

FY 2021100.0%FY 2022100.0%FY 2023100.0%FY 2024100.0%FY 202586.0%
100.0%86.0%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

2

Insider sells · 90 days

Earnings

Last report: 10-Q filed May 7, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • 8-K eventAnnual Meeting ResultsJun 22, 2026Filing
  • Insider sellInsider Sell $246K · 10b5-1 PlanOkey Stephanie · Director · $246.1KJun 18, 2026Filing
  • 8-K eventEarnings ReleaseMay 7, 2026Filing
  • Quarterly report10-Q FiledMay 7, 2026Filing
  • Insider sellInsider Sell $3.4M · 10b5-1 PlanKnight Jeff E. · Chief Dev. & Operating Officer · $3.4MApr 10, 2026Filing
  • 8-K eventConsultant AgreementApr 10, 2026Filing

Questions

Frequently asked questions

What is Crinetics Pharmaceuticals, Inc.'s market cap?

Crinetics Pharmaceuticals, Inc. (CRNX) has a market capitalization of $3.7B.

What is CRNX's P/E ratio?

A meaningful P/E ratio is not available for CRNX — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.

What is CRNX's price-to-book (P/B) ratio?

CRNX trades at 3.78 times book value per share.

Are insiders buying CRNX stock?

SEC Form 4 filings show no open-market insider buys at Crinetics Pharmaceuticals, Inc. in the last 90 days (2 sells).

Same arena

Related companies in Biotechnology

ACAD

ACADIA Pharmaceuticals Inc.

$3.7B

VCYT

Veracyte, Inc.

$3.8B

DNTH

Dianthus Therapeutics, Inc.

$3.8B

CPRX

Catalyst Pharmaceuticals, Inc.

$3.8B

KNSA

Kiniksa Pharmaceuticals, Ltd.

$3.7B

NAMS

NewAmsterdam Pharma Company N.V.

$3.9B

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.